Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.

Abstract

The core-binding factor (CBF) leukemias comprise acute myeloid leukemia (AML) with t(8;21) and inv(16)/t(16;16), characterized by the presence of the AML1-ETO and CBFbeta-MYH11 fusion genes, respectively. These leukemia-associated genes can now be sensitively and reliably quantified by real-time reverse transcription polymerase chain reaction (RT-PCR) techniques and thus can serve as molecular targets for monitoring residual leukemia. Studies to date suggest that quantitative monitoring of minimal residual disease (MRD) in CBF-positive AML is useful in distinguishing patients at high risk of relapse from those in durable remission. Preliminary results of MRD monitoring by real-time RT-PCR in this subset of AML patients are promising and provide the basis for further evaluation by quantitative analysis in large prospective clinical trials.

• Authors: John A Liu Yin, Lindsay Frost
• Journal: Current oncology reports (Curr Oncol Rep) Vol. 5 Issue 5 Pg. 399-404 (Sep 2003) ISSN: 1523-3790 [Print] United States
• PMID: 12895392 (Publication Type: Journal Article)

Chemical References

• AML1-ETO fusion protein, human
• CBFbeta-MYH11 fusion protein
• Core Binding Factor Alpha 2 Subunit
• Oncogene Proteins, Fusion
• RNA, Neoplasm
• RUNX1 Translocation Partner 1 Protein
• Transcription Factors

Topics

• Acute Disease
• Core Binding Factor Alpha 2 Subunit
• Humans
• Leukemia, Myeloid (metabolism, therapy)
• Monitoring, Physiologic
• Neoplasm, Residual
• Oncogene Proteins, Fusion (genetics, metabolism)
• Polymerase Chain Reaction
• Prognosis
• RNA, Neoplasm (metabolism)
• RUNX1 Translocation Partner 1 Protein
• Transcription Factors (genetics, metabolism)